Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
04/1999
04/07/1999CN1213306A Novel substituted imidazolium compounds
04/07/1999CN1213305A Novel cycloalkyl substituted imidazolium compounds
04/07/1999CN1213282A Oral peptide pharmaceutical products
04/07/1999CN1212875A Traditional Chinese medicine prescription for treating ischialgia disease
04/06/1999US5891878 Enzyme inhibitors of phosphodiesterase or tumor necrosis factor
04/06/1999US5891868 Methods for treating postmenopausal women using ultra-low doses of estrogen
04/06/1999US5891865 Treatment of arthritic disease induced by infectious agents
04/06/1999US5891863 Prevent resorption of prosthetic bone
04/06/1999US5891672 Polynucleotides encoding GTP cyclohydrolase II (ribA)
04/06/1999US5891670 Tetracycline resistance protein
04/01/1999WO1999015635A1 Human ste20-like stress activated serine/threonine kinase
04/01/1999WO1999015529A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
04/01/1999WO1999015508A1 Vitronectin receptor antagonists
04/01/1999WO1999015507A1 Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates
04/01/1999WO1999015506A1 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same
04/01/1999WO1999015494A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
04/01/1999WO1999015493A1 9,10-dihydro-9,10-ethanoanthracene derivatives as phospholipase inhibitors
04/01/1999WO1999015490A1 C3a receptor ligands
04/01/1999WO1999015178A1 Vitronectin receptor antagonist
04/01/1999WO1999015170A1 Vitronectin receptor antagonist
04/01/1999WO1999015164A1 Amide derivatives for the treatment of diseases mediated by cytokines
04/01/1999WO1999015160A2 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies
04/01/1999WO1999015155A1 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
04/01/1999WO1999003878A3 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis
04/01/1999WO1999003826A3 Metalloproteinase inhibitors
04/01/1999CA2304879A1 New tetracycles, process for their production and pharmaceutical preparations containing these compounds
04/01/1999CA2304000A1 Vitronectin receptor antagonist
04/01/1999CA2303943A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
04/01/1999CA2303918A1 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies
04/01/1999CA2303883A1 C3a receptor ligands
04/01/1999CA2303846A1 Vitronectin receptor antagonist
04/01/1999CA2303487A1 Vitronectin receptor antagonists
04/01/1999CA2300051A1 Amide derivatives for the treatment of diseases mediated by cytokines
04/01/1999CA2246004A1 A kringle-related clone, hthbz47
03/1999
03/31/1999EP0905248A1 Staphylococcus aureus MurE protein and nucleic acids encoding it
03/31/1999EP0905243A2 Polynucleotides from Staphylococcus aureus expressed in infected tissue
03/31/1999EP0905237A2 PIGR-2 A member of immunoglobulin gene superfamily
03/31/1999EP0905233A2 Staphylococcus aureus trigger factor
03/31/1999EP0904284A1 6-substituted amino-4-oxa-1-azabicyclo (3,2,0) heptan-7-one derivatives as cysteine protease inhibitors
03/31/1999EP0904278A1 Apoptosis inducing molecule ii
03/31/1999EP0904272A1 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
03/31/1999EP0904270A1 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
03/31/1999EP0904260A1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids
03/31/1999EP0904099A1 A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
03/31/1999EP0904094A1 Treatment of bone disorders with adrenomedullin
03/31/1999EP0904092A1 Purified extract of harpagophytum procumbens and/or harpagophytum zeyheri dence, process for its production and its use
03/31/1999EP0904061A1 Pharmaceutical composition with base of rhein or diacerhein with improved biological availability
03/31/1999CN1212689A Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
03/31/1999CN1212628A Method of promoting bone growth with hyaluronic acid and growth factors
03/31/1999CN1212620A Mercapto derivatives as inhibitors of cyclooxygenases
03/31/1999CN1042730C Method for preparing pyrazolopyridine compound
03/30/1999US5889000 Naphthofluorene compounds, intermediates, compositions and methods
03/30/1999US5888991 Use of phosphorus derivatives of alkaloids for treating endocrinopathies
03/30/1999US5888963 Treatment of bone disorders with adrenomedullin
03/30/1999US5888771 Gene products as targets for the development of antibiotics.
03/30/1999US5888770 Spoiiie
03/30/1999US5888510 Administering antibody
03/30/1999CA2157927C Therapeutic uses of bactericidal/permeability increasing protein produc ts
03/30/1999CA2047216C 9-substituted-8-unsubstituted-9-deazaguanines
03/25/1999WO1999014346A2 SENSE mRNA THERAPY
03/25/1999WO1999014340A1 Human prl-1 phosphatase
03/25/1999WO1999014231A2 Bifidus stimulating peptides and its uses
03/25/1999WO1999014195A1 2-aminopyridines as inhibitors of cyclooxygenase-2
03/25/1999WO1999013888A1 Germicidal compositions for the treatment of animal infectious diseases of the hoof, comprising a copper salt, a quaternary ammonium compound and a peroxide
03/25/1999WO1998051665A3 Novel macrocyclic compounds as metalloprotease inhibitors
03/25/1999WO1998050032A9 BETA-LACTAM INHIBITORS OF CoA-IT
03/25/1999DE19742014A1 Use of new and known tetracyclene compounds as phospholipase inhibitors
03/25/1999CA2304982A1 Sense mrna therapy
03/25/1999CA2303227A1 Human prl-1 phosphatase
03/25/1999CA2244971A1 Mure
03/24/1999EP0903353A1 Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them
03/24/1999EP0902779A2 Phosphate mimics
03/24/1999CN1211991A Compounds with growth hormone releasing properties
03/24/1999CN1211921A Benzothiophenes, formulations containing same and process of preparing same
03/24/1999CN1211917A Pharmaceutical composition with base of rhein or diacerhein with improved biological availability
03/24/1999CN1211437A Ointment for treating spur and its preparation method
03/24/1999CN1042633C Alkoxy alkyl carbamates from imidazo (1,2-a) pyridines
03/23/1999US5885964 Administering to the patient suffering from osteoporosis an effective amount of an agent comprising kininogen or kininogen peptide to prevent bone resorption
03/18/1999WO1999013055A1 Human sigma receptor
03/18/1999WO1999013054A2 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
03/18/1999WO1999012970A1 Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds
03/18/1999WO1999012961A1 Estrogen receptor
03/18/1999WO1999012944A2 SYNTHETIC DIVALENT sLex CONTAINING POLYLACTOSAMINES AND METHODS FOR USE
03/18/1999WO1999012930A1 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors
03/18/1999WO1999012915A1 Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals
03/18/1999WO1999012898A1 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
03/18/1999WO1999012896A1 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
03/18/1999WO1999012895A1 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
03/18/1999WO1999012894A1 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
03/18/1999WO1999012567A1 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
03/18/1999WO1999012561A2 FRACTURE HEALING USING PTHrP ANALOGS
03/18/1999WO1999012559A1 Inhibition of apoptotis using prosaposin receptor agonists
03/18/1999WO1999012551A1 Method of increasing bone volume using non-naturally-occurring fp selective agonists
03/18/1999WO1999012550A1 Method of increasing bone volume
03/18/1999WO1998058911A3 Prostaglandin agonists
03/18/1999WO1998056909A3 Secreted proteins and polynucleotides encoding them
03/18/1999CA2304108A1 Inhibition of apoptotis using prosaposin receptor agonists
03/18/1999CA2303800A1 Method of increasing bone volume using non-naturally-occurring fp selective agonists
03/18/1999CA2303799A1 Method of increasing bone volume
03/18/1999CA2303479A1 Human sigma receptor
1 ... 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 ... 820